Skora, Andrew D.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 9,377

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences

Cancer Immunotherapy and BiomarkersImmune cells in cancer

Cited by 676

Targeting a neoantigen derived from a common TP53 mutation

Hsiue, E. H.-C., Wright, K. M., Douglass, J., Hwang, M. S., Mog, B. J., Pearlman, A. H., Paul, S., DiNapoli, S. R., Konig, M. F., Wang, Q., et al. (2021) · Science

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 367

Bispecific antibodies targeting mutant RAS neoantigens

Douglass, J., Hsiue, E. H.-C., Mog, B. J., Hwang, M. S., DiNapoli, S. R., Pearlman, A. H., Miller, M. S., Wright, K. M., Azurmendi, P. A., Wang, Q., et al. (2021) · Science Immunology

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 171